AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

More about the company

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Delayed OTC Markets Other stock markets 10:27:29 28/05/2026 pm IST			5-day change	1st Jan Change
1.120 ^USD	-.--%		-.--%	-22.76%

13/07	AB Science to Discontinue Three Masitinib-related Clinical Studies	MT
10/07	AB Science streamlines its portfolio and refocuses on two molecules

Market Cap	4.46Cr 5.08Cr 4.15Cr 3.81Cr 7.15Cr 491.62Cr 7.28Cr 50Cr 19Cr 239.79Cr 19Cr 19Cr 831.91Cr	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	4.46Cr 5.08Cr 4.15Cr 3.81Cr 7.15Cr 491.62Cr 7.28Cr 50Cr 19Cr 239.79Cr 19Cr 19Cr 831.91Cr	EV / Sales 2026 *	37.2x	EV / Sales 2027 *	34.3x
Free-Float	63.24%	Yield 2026 *	-	Yield 2027 *	-

13/07	AB Science to Discontinue Three Masitinib-related Clinical Studies	MT
10/07	AB Science streamlines its portfolio and refocuses on two molecules
10/07	AB Science SA Provides Update on Clinical Program, Suspends Non-Priority Clinical Trials and Focuses on Ab8939 and Masitinib Programs	CI
08/07	Stéphane Ledermann takes the helm at AB Science as CEO
07/07	AB Science S.A. Announces Board Changes	CI
07/07	AB Science S.A. Announces CEO Changes	CI
03/07	AB Science S.A. announced that it has received $2.01616 million in funding	CI
01/07	AB Science, successful private placement
01/07	AB Science S.A. announced that it has received ?2.294 million in funding	CI
29/06	AB Science Reports Completion of Step 3 of Phase 1 Evaluating Combination of Ab8939 with Venetoclax for Treatment of Refractory or Relapsed Acute Myeloid Leukemia	CI
29/06	AB Science completes Step 3 of a Phase 1 study
18/06	AB Science Secures US Patent for Prostate Cancer Therapy	MT
18/06	AB Science Secures New U.S. Patent for Masitinib

10/07	AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs	GL
08/07	AB Science : Board of Directors is restructuring its governance to usher in a new phase in the company’s development	PU
01/07	AB Science announces the successful completion of a EUR 2.3 million private placement	GL
29/06	AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML	GL
29/06	AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML	AQ

AB Science Share Price OTC Markets

Stocks

ABSCF

FR0010557264

Pharmaceuticals

Valuation: AB Science

Chart: AB Science

Latest news : AB Science

Last Transcript: AB Science

Press Releases: AB Science

News in other languages: AB Science

Quotes and Performance

Course Extremes

Managers and Directors: AB Science

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Income Statement and Estimates

Quarterly revenue - Rate of surprise

13/07	Bourse : Go West pour Stellantis, Apple se fâche contre OpenAI, Akzo courtisé
13/07	Wall Street ne chômera pas le 14 juillet
10/07	AB Science rationalise son portefeuille et se recentre sur deux molécules
10/07	AB Science fait le point sur son programme clinique avec l’arrêt de certaines études cliniques non prioritaires en vue de se concentrer sur deux programmes cliniques
08/07	Stéphane Ledermann prend les rênes d'AB Science en tant que PDG

Current year	1.12	1.37
1 year	1.12	1.45
3 years	0	4.46
5 years	0	18.78
10 years	0	26.7

Manager	Title	Age	Since
Stéphane Ledermann CEO	Chief Executive Officer	-	07/07/2026
Laurent Guy DFI	Director of Finance/CFO	-	20/11/2009
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	01/04/2018

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	11/07/2001
Patrick Moussy BRD	Director/Board Member	-	20/09/2011
Cécile de Guillebon BRD	Director/Board Member	64	27/06/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	-.--%	-.--%	-	-	5.1Cr
MERCK & CO., INC.	+2.32%	+1.91%	+54.88%	+19.56%	31TCr
MERCK KGAA	+1.72%	+0.94%	+24.00%	-11.62%	6.79TCr
HALOZYME THERAPEUTICS, INC.	+4.29%	+4.27%	+38.06%	+89.08%	923.05Cr
KYOWA KIRIN CO., LTD.	-1.26%	-1.72%	+4.64%	-3.98%	843.12Cr
SK BIOPHARMACEUTICALS CO., LTD.	+3.78%	+1.92%	-21.25%	-6.67%	407.28Cr
BETTA PHARMACEUTICALS CO., LTD.	+0.07%	-9.52%	-5.52%	+22.21%	377.19Cr
YUHAN CORPORATION	+1.71%	+2.73%	-42.88%	+11.90%	354.49Cr
SUPERNUS PHARMACEUTICALS, INC.	+0.94%	-2.41%	+42.71%	+56.57%	272.44Cr
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-0.30%	-6.60%	+4.82%	-10.21%	213.28Cr
Average	+1.32%	+1.41%	+11.05%	+18.54%	4.63TCr
Weighted average by Cap.	+2.17%	+3.21%	+45.99%	+15.33%

	2026 *	2027 *
Net sales	12L 13.64L 11.15L 10.25L 19.23L 13Cr 19.57L 1.33Cr 52L 6.44Cr 51.22L 50.11L 22Cr	13L 14.78L 12.08L 11.11L 20.83L 14Cr 21.2L 1.44Cr 56.33L 6.98Cr 55.49L 54.29L 24Cr
Net income	-	-
Net Debt	-	-